ArticleJournal of ovarian research2026
Bioinformatics and clinical analysis of CETN2's impact on platinum resistance and prognosis in epithelial ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of centrin-2 (CETN2) in platinum resistance and its underlying mechanisms in ovarian cancer.
methodsWe conducted a pan-cancer analysis of CETN2 expression and its associated genes using the STRING and TIMER databases. Data from the GEO and TCGA databases were employed for survival, clinical correlation, and prognostic analyses. Enrichment and co-expression analyses were performed to identify relevant pathways and genes. We also analyzed the tumor microenvironment, immune checkpoints, and drug sensitivity. For clinical validation, quantitative real-time PCR was used to measure CETN2 expression in patient samples and assess its correlation with chemotherapy response. Predictive models, including logistic regression and decision trees, were constructed. Their performance in predicting chemotherapy outcomes was evaluated using receiver operating characteristic (ROC) curves, and the prognostic impact of CETN2 was assessed via Kaplan-Meier survival analysis.
resultsCETN2 mRNA expression was significantly elevated in cisplatin-resistant samples. CETN2 was associated with the nucleotide excision repair (NER), oxidative phosphorylation, and cell cycle pathways and showed a negative correlation with several immune checkpoints. CETN2 expression demonstrated notable predictive value for chemotherapy response, particularly in platinum-sensitive ovarian cancer. It influenced stromal and immune-related scores in the tumor microenvironment, and differential expression levels correlated with significant variations in sensitivity to specific drugs. In clinical samples, CETN2 expression was linked to immune infiltration patterns. Protein expression of CETN2 was significantly higher in platinum-resistant patients compared to platinum-sensitive patients and showed predictive utility for chemotherapy outcomes.
conclusionUpregulation of CETN2 may contribute to cisplatin resistance through pathways involving nucleotide excision repair, oxidative phosphorylation, and the cell cycle. CETN2 holds potential as a biomarker for platinum-based chemotherapy response and prognostic evaluation in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.